You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康希諾(688185.SH):簽署重組脊髓灰質炎疫苗及相關聯合疫苗項目資助協議
格隆匯 10-09 16:14

格隆匯10月9日丨康希諾(688185.SH)公佈,公司於2023年10月與比爾及梅琳達·蓋茨基金會(簡稱“蓋茨基金會”)簽署了關於重組脊髓灰質炎疫苗的項目資助協議。具體內容詳見公司於2023年10月25日在上海證券交易所網站披露的《自願披露關於與比爾及梅琳達·蓋茨基金會簽署重組脊髓灰質炎疫苗項目資助協議的公吿》。基於重組脊髓灰質炎疫苗研發工作的持續推進,公司近日與蓋茨基金會簽署協議,將繼續收到重組脊髓灰質炎疫苗項目的資助,同時新增對包含該款重組脊髓灰質炎疫苗的聯合疫苗項目的支持。

根據此次簽署的協議,公司將收到蓋茨基金會提供的合計超過1,700萬美元的項目資助,以支持公司基於病毒樣顆粒(virus-likeparticle,VLP)的脊髓灰質炎疫苗的進一步開發,主要包括臨牀研究、工藝開發及規模擴大等工作;同時支持包含該款重組脊髓灰質炎疫苗的聯合疫苗的研發。蓋茨基金會將根據項目研發目標/里程碑的達成情況,按約定的付款時間表分階段支付項目資助。

重組脊髓灰質炎疫苗基於公司的蛋白結構設計和VLP組裝技術開發,是一種非傳染性脊髓灰質炎疫苗,在生產過程中不依賴活病毒,預期具有良好的安全性和免疫原性。非傳染性的VLP技術路線脊髓灰質炎疫苗被世界衞生組織推薦作為未來消滅脊髓灰質炎的首選疫苗之一,有望為全球根除脊髓灰質炎作出貢獻。同時,該候選疫苗也可成為聯合疫苗的組成部分,加入聯合疫苗將有利於更廣泛地推廣,從而消滅脊髓灰質炎。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account